Voyager Therapeutics, Inc.(VYGR)Earnings, Financials & Key RatiosVoyager Therapeutics, Inc. (VYGR) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash runway is rapidly diminishing, with cash and equivalents falling to $43.3 million in 2026Q1 against a quarterly burn rate that consistently exceeds $30 million.
Voyager Therapeutics, Inc. (VYGR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Voyager Therapeutics, Inc. (VYGR) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.47vs $0.54+13.0% | $3Mvs $9M-70.5% |
| Q2 2026 | May 5, 2026 | $0.47vs $0.54+13.0% | $3Mvs $9M-70.5% |
| Q2 2026 | Mar 9, 2026 | $0.46vs $0.54+14.8% | $15Mvs $10M+46.2% |
| Q4 2025 | Nov 10, 2025 | $0.47vs $0.53+11.3% | $13Mvs $10M+27.4% |
Recent stock market news and headlines for Voyager Therapeutics, Inc. (VYGR)
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul.
LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year.
Key metrics vs top competitors for Voyager Therapeutics, Inc. (VYGR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.78 | $228.39M | -1.85 | -49.53% | -296.53% | -48.29% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — |
Voyager Therapeutics, Inc. (VYGR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Voyager Therapeutics, Inc. (VYGR) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Apr 21, 2026·SEC
Mar 9, 2026·SEC
Get notified when VYGR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Voyager Therapeutics, Inc. (VYGR) stock FAQ — growth, dividends, profitability & financials explained
Voyager Therapeutics, Inc. (VYGR) reported $36.5M in revenue for fiscal year 2025.
Voyager Therapeutics, Inc. (VYGR) saw revenue decline by 49.5% over the past year.
Voyager Therapeutics, Inc. (VYGR) reported a net loss of $116.6M for fiscal year 2025.
Voyager Therapeutics, Inc. (VYGR) has a return on equity (ROE) of -48.3%. Negative ROE indicates the company is unprofitable.
Voyager Therapeutics, Inc. (VYGR) had negative free cash flow of $129.9M in fiscal year 2025, likely due to heavy capital investments.
